bisacodyl / Generic mfg. - LARVOL DELTA

Effects of Constipation Treatment in Chronic Kidney Disease: A Pilot Feasibility Trial (clinicaltrials.gov) - P=N/A | N=14 | Completed | Sponsor: University of Tennessee | Recruiting ➔ Completed | N=40 ➔ 14

Enrollment change • Trial completion • Chronic Kidney Disease • Constipation • Gastroenterology • Gastrointestinal Disorder • Nephrology • Renal Disease

Effects of Constipation Treatment in Chronic Kidney Disease: A Pilot Feasibility Trial (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: University of Tennessee | Trial primary completion date: Jun 2025 ➔ Nov 2025 | Trial completion date: Jul 2025 ➔ Nov 2025

Trial completion date • Trial primary completion date • Chronic Kidney Disease • Constipation • Gastroenterology • Gastrointestinal Disorder • Nephrology • Renal Disease

G Protein-Coupled Receptor 35 Holds Potential as a Beacon of Hope for Treating Chondrosarcoma. (PubMed, Balkan J Med Genet) - "G protein-coupled receptors are widely known targets for cancer treatment. Here, we showed that bisacodyl can be a potential therapeutic agent in chondrosarcoma cell lines."

Journal • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • CHEK2

Myxedema Ileus: A Rarely Reported Colonic Manifestation of Myxedema Coma (ACG 2025) - "The patient was started on levothyroxine, liothyronine, and hydrocortisone. Due to concern for ileus, the patient was started on a bowel regimen including docusate-senna, bisacodyl, and polyethylene glycol without resolution of his ileus...In this case, myxedema ileus resolved with treatment of myxedema coma following administration of levothyroxine and liothyronine, as well as treatment with laxatives and gastrografin enema. Myxedema coma has a high patient mortality and early recognition of manifestations such as myxedema ileus is important to prevent further complications.Figure: Distended bowel loops throughout the abdomen noted on x-ray, suggestive of ileus."

Cardiovascular • CNS Disorders • Endocrine Disorders • Heart Failure • Hypoglycemia • Mood Disorders

Comparing Safety and Efficacy of Different Bowel Preparation Regimens in Constipated Patients Undergoing Colonoscopy: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (ACG 2025) - "Fifteen RCTs were included in this network meta-analysis. Compared to 4L PEG (polyethylene glycol), 3L PEG + 3d-Lin (3 days-Linaclotide) (RR=1.29; 95%CI:[1.12,1.47], p=0.0002), 4L PEG + 1d-Lin (RR=1.25; 95%CI:[1.04,1.51], p=0.02), NaP (sodium phosphate) + bisacodyl (RR=1.52; 95%CI:[1.09,2.10], p=0.01) and Probiotic 14d + NaP (RR= 3.59; 95%CI:[1.83,7.04], p=0.0002) arms significantly increased the adequate bowel preparation with Probiotic 14d + NaP group ranked highest and Senna + MgSO4 (Magnesium sulphate) ranked lowest regarding this outcome. The risk of all other adverse effects, including nausea, vomiting, and bloating, was comparable between different regimens, except abdominal pain, which was significantly reduced in the 3L PEG + 3d-Lin arm (RR=0.18; 95%CI:[0.04,0.88], p=0.03) compared to 4L PEG. In constipated patients, Probiotic 14d + NaP showed the highest efficacy for adequate bowel preparation, while Senna + MgSO4 was least effective."

Retrospective data • Review • Constipation • Gastroenterology • Gastrointestinal Disorder

Preventing Inadequate Colonoscopy Bowel Preparation With the Targeted Addition of Adjuncts: A Quality Improvement Study (ACG 2025) - "This study evaluates the impact of using an alternative enhanced prep regimen consisting of combining 15 mg bisacodyl to 4L PEG-3350 on a split schedule for patients at risk for inadequate prep. This was a quality improvement project... Of 2027 outpatient colonoscopies performed during the study period, 446 high risk patients were identified (102 patients with prior inadequate prep and 344 with risk factors) and prescribed the enhanced regimen. 86.8% were males. Average age was 64."

Addiction (Opioid and Alcohol) • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Metabolic Disorders • Obesity

Hypertensive Emergency: Moving Fast to Correct Slow Transit Constipation (ACG 2025) - "Despite treatment with oral antihypertensive therapy and intravenous morphine, his symptoms persisted with worsening systolic pressures greater than 200 mmHg...For his severe constipation, polyethylene glycol, senna, lactulose, and bisacodyl suppositories were administered...In cases such as this, it is important to consider this mechanism to provide timely management and attempt to reduce the morbidity and mortality associated with hypertensive emergencies.Figure: Figure 1.A. Portable Upright Abdominal X-ray B. Portable Supine Abdominal X-ray"

Cardiovascular • Colorectal Cancer • Constipation • Diabetes • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Hypertension • Metabolic Disorders

Bisacodyl-Induced Ischemic Colitis Following Colonoscopy Preparation in a 58-Year-Old Female: A Case Report (ACG 2025) - "Further studies are warranted to clarify the incidence and risk factors for stimulant laxative-induced ischemic colitis. Figure: Friable mucosa in splenic flexure Figure: Friable, erythematous mucosa in the descending colon"

Case report • Clinical • Asthma • Cardiovascular • Colonic Polyps • Dermatology • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Immunology • Metabolic Disorders • Respiratory Diseases

Preparing for Success: Enhanced Bowel Preparation Protocol Significantly Reduces Inadequate Colonoscopy Preparation, a Retrospective Study of 1,850 Patients (ACG 2025) - "Variables assessed included demographic characteristics (age, gender, BMI), comorbidities (e.g., diabetes, cirrhosis, stroke, dementia, IBD, constipation), prior abdominal surgery, ASA class, functional status, incarceration status, substance use (alcohol, tobacco, marijuana), and medication use (narcotics, benzodiazepines, methadone, tricyclic antidepressants [TCAs], other antidepressants, anticholinergics, antipsychotics, laxatives). Factors independently associated with poor bowel preparation included anticholinergic use (OR 1.4, p = 0.007), baseline laxative use (OR 1.77, p = 0.008), higher ASA class (OR 1.77, p < 0.001), and marijuana use (OR 1.9, p = 0.018). TCA use demonstrated a trend toward significance (OR 1.8, p = 0.072). Following implementation of the updated protocol, "excellent" preparation rates improved from 35.51% to 42.49%, and "poor" preparation rates decreased from 3.78% to 1.62% (χ² = 11.65, p = 0.009)."

Retrospective data • Addiction (Opioid and Alcohol) • Alzheimer's Disease • Cardiovascular • CNS Disorders • Constipation • Dementia • Diabetes • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Metabolic Disorders

Prevalence and Prescription Patterns of IBS Treatments Across Demographic and Socioeconomic Factors (ACG 2025) - "The most commonly prescribed IBS-D medication was loperamide (4%), with prescription IBS-D drugs also used in only 2%...Black patients were more likely to be prescribed stimulant laxatives, particularly bisacodyl (10% vs. 4% in White and 2% in Asian patients)... Among 390,202 individuals in the database, 3.9% (n=14,897) were diagnosed with IBS. The majority (57%) were diagnosed between 36 and 65 years of age, were White (73%) and female (78%). The most commonly used medications for IBS-C were osmotic laxatives (18%), stimulant laxatives (9%), and fiber (6%)."

CNS Disorders • Gastrointestinal Disorder

Bowel Regimen Gone Rogue: A Rare Case of Anaphylaxis Secondary to Over-the-Counter Polyethylene Glycol 3350 (ACG 2025) - "He was given IV methylprednisolone sodium succinate 125mg, IV famotidine 20mg, IV diphenhydramine 25mg and started on an epinephrine infusion...Options without polyethylene glycols or polysorbates include sodium picosulfate, magnesium oxide, anhydrous citric acid; sodium phosphate tablets; oral sulfate solution/tablets; magnesium citrate; bisacodyl; and off label lactulose2.Citations: (1) Stone et al...April 2025. DOI: 10.1053/j.gastro.2025.02.002."

Clinical • Colorectal Cancer • Constipation • Dermatology • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hypotension • Immunology • Metabolic Disorders • Pruritus • Solid Tumor

A Case of Polyethylene Glycol-Induced Ischemic Colitis (ACG 2025) - "Prior case reports have described bisacodyl and PEG with bisacodyl-associated ischemic colitis; however, no prior case reports describe ischemic colitis with PEG alone. While PEG is considered highly safe and efficacious, this case is suggestive of an infrequent episode of PEG-induced ischemic colitis.Figure: Localized erythema and shallow ulcerations of the splenic flexure.Figure: Erythema and ulceration of the sigmoid colon."

Clinical • Atherosclerosis • Colorectal Cancer • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Metabolic Disorders • Osteoarthritis • Rheumatology • Solid Tumor • CRP

Defecation Patterns in Constipated Patients (clinicaltrials.gov) - P=N/A | N=130 | Recruiting | Sponsor: The California Medical Innovations Institute, Inc. | Suspended ➔ Recruiting | Trial completion date: Mar 2026 ➔ Dec 2026 | Trial primary completion date: Mar 2025 ➔ Dec 2026

Enrollment open • Trial completion date • Trial primary completion date • Constipation • Gastroenterology • Gastrointestinal Disorder

MRI ASSESSMENT OF ACUTE COLONIC VOLUME RESPONSES TO OPIOIDS AND NALOXEGOL IN HEALTHY SUBJECTS: INTERIM RESULTS FROM A RANDOMISED, DOUBLE-BLIND CROSSOVER STUDY (UEGW 2025) - "During each visit, five abdominal MRI scans (each 20 min.) are obtained at 30 min intervals, at baseline, after drug intake, after a standardized 44 g oatmeal and 100 mL Nutridrink (313 kCal) meal, after a second drug dose, and after a bisacodyl 10 mg suppository administration. Interim MRI analysis of 8 HVs suggests different colonic motility responses across groups and timepoints. Toilet visits were suppressed in both codeine groups. Different responses to drug and food intake were found in the ascending and descending colon between the naloxegol+codein and double placebo group on one hand compared to the codein+placebo group."

Clinical • Constipation • Gastroenterology • Gastrointestinal Disorder

EFFICACY AND SAFETY OF PYRIDOSTIGMINE FOR SEVERE CHRONIC CONSTIPATION REFRACTORY TO FIRST-LINE TREATMENTS (UEGW 2025) - "Aims & We carried out a retrospective observational study involving all patients diagnosed with functional constipation (constipation-predominant irritable bowel syndrome [IBS-C] or chronic idiopathic constipation) according to the Rome IV criteria, who met the criteria for severe chronic constipation (2) (defined as two or fewer spontaneous and complete bowel movements per week for a minimum of 6 months, associated with hard stools, sensation of incomplete evacuation, or straining during defecation in at least 25% of bowel movements), who were refractory to first-line treatments (dietary and lifestyle counseling, bulk-forming laxatives, osmotic laxative such as polyethylene glycol and stimulant laxative such as bisacodyl) and who were treated with pyridostigmine in our outpatient gastroenterology clinic from April 2021 to December 2024... In our cohort, pyridostigmine was an effective and safe treatment for IBS-C and chronic idiopathic constipation in patients..."

Clinical • CNS Disorders • Constipation • Dyspepsia • Fatigue • Gastroenterology • Gastrointestinal Disorder • Myasthenia Gravis

ENHANCEMENT OF SENNOSIDES AVAILABILITY IN CHRONIC CONSTIPATION VIA CO-ADMINISTRATION WITH MESALAZINE (UEGW 2025) - "Stimulant laxatives provide quick relief and are preferred by patients and pharmaceutical companies; "sennosides" and "bisacodyl," are more popular compared with bulk-forming laxatives2)... Sennosides is predicted to provoke IL-2 and IFN-γ biosynthesis that induces killer T cell aggregation and subsequent IL-1β production. As the combination group did not show any inflammation, it is assumed that mesalazine prohibits the inflammatory process. These results provide further evidence to indicate that mesalazine can alleviate sennosides-induced inflammation without adversely affecting its efficacy."

Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Immunology • Inflammation • Inflammatory Bowel Disease • Nephrology • Renal Disease • IFNG • IL1B • IL2

AGE, BMI, AND BOWEL HABITS AS PREDICTORS OF PATENCY CAPSULE FAILURE IN PATIENTS PREPARED WITH A PRO-MOTILITY PROTOCOL (UEGW 2025) - "Aims & This retrospective study aimed to evaluate factors associated with PC failure in patients undergoing a pro-motility preparation protocol, consisting of a low-residue diet, followed by a liquid diet and administration of 10 mg bisacodyl at the time of PC ingestion... In patients undergoing patency capsule testing with a pro-motility protocol, PC failure was mainly associated with higher BMI and infrequent bowel movements. A CRT model identified bowel frequency, age, and BMI as key predictors of failure, revealing distinct high- and low-risk profiles. These findings support the use of simple clinical parameters in pre-test assessment to improve patient selection and enhance test success."

Clinical • Anemia • Crohn's disease • Diabetes • Gastroenterology • Hematological Disorders • Immunology • Inflammatory Bowel Disease • Metabolic Disorders • Obesity

NON-INVASIVE BODY SURFACE COLONIC MAPPING CORRELATES WITH REAL-TIME SYMPTOMS IN PATIENTS WITH REFRACTORY SLOW-TRANSIT CONSTIPATION (UEGW 2025) - "Simultaneous HRCM and BSCM recordings were obtained during a 1-hour fasting period, 1 hour after a standardized low-fat meal, and 1 hour after luminally applied 10 mg of bisacodyl... BSCM is an easy-to-apply, painless, non-invasive tool that has the potential to elucidate underlying mechanisms driving symptoms in patients with refractory STC. Relating colonic motility to symptoms could aid in developing a more personalized approach to manage these patients' clinical treatment pathway"

Clinical • Non-invasive • Constipation • Gastroenterology • Gastrointestinal Disorder

DOUBLE-BLIND PLACEBO-CONTROLLED CROSS-OVER MRI STUDY EVALUATING THE ACUTE EFFECT OF CODEINE AND NALOXEGOL ON GASTRIC CONTENT VOLUMES AND MOTILITY IN HEALTHY VOLUNTEERS (UEGW 2025) - "in between the scans, comprising one baseline fasted MRI, one MRI after the intake of either of the three drug combinations: 25 mg naloxegol + 60 mg codeine, 60 mg codeine + placebo, or double placebo, one after a standardized meal with 44 g oatmeal and 100 mL Nutridrink (313 kCal), followed by an MRI scan after a second dose of either 30 mg codeine or placebo, and a final scan after a bisacodyl 10 mg suppository administration. Interim analysis of 10 HVs using cine-MRI revealed significant codeine-induced delays in gastric emptying compared to placebo. However, no significant differences were currently observed between codeine with and without naloxegol, and this will be reassessed on the entire study sample size. Nevertheless, gastric motility revealed only a tendency toward more contractility of the whole stomach but not of the antrum with placebo."

Clinical • Constipation • Gastroenterology • Gastrointestinal Disorder

OPTIMIZING COLONOSCOPY PREPARATION IN END STAGE RENAL DISEASE: A TAILORED LOW-VOLUME APPROACH (UEGW 2025) - "A personalized preparation protocol was implemented between 06/2024-02/2025, including a 5-days low-fiber diet, daily bisacodyl, tailored fluid intake, and reduced-volume PEG 3350 with ascorbic acid (PtESRD group)... This proof-of-concept study shows that the PtESRD protocol improves bowel preparation and colonoscopy completion rates in hospitalized ESRD transplant candidates. Its independent predictive value supports its use and highlights the potential of tailored protocols in high-risk patients. Further prospective studies are needed to confirm these findings and guide broader implementation."

Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease

Comparative Cleansing Efficacy, Safety, and Tolerability of Bowel Preparation Agents in Pediatric Patients: A Network and Proportional Meta-Analyses of Randomized Controlled Trials. (PubMed, Dig Dis Sci) - "Sodium picosulfate with magnesium citrate offers the most favorable balance of efficacy, safety, and tolerability for pediatric colonoscopy preparation. PEG-3350 (Miralax) may be considered when maximized cleansing is the goal, but additional efficacy and tolerability data in children are needed. PROSPERO registration number: CRD42024508556."

Journal • Pain • Pediatrics

Optimising Magnetic Resonance Imaging of the Prostate Gland (ESUR 2025) - "Bowel preparation can be performed with a micro-enema or oral laxative such as bisacodyl...Some preliminary evidence suggest that a higher PI-QUAL score increases detection of csPCa. However, we recognize that the PI-QUAL scoring system is new and further validation from large-scale prospective studies on its clinical utility is required."

MRI • Benign Prostatic Hyperplasia • Genito-urinary Cancer • Infectious Disease • Prostate Cancer • Solid Tumor

Oral bowel cleansers and ischemic colitis risk: A real-world disproportionality analysis. (PubMed, PLoS One) - "To our knowledge, this is one of the largest pharmacovigilance analyses exploring ischemic colitis associated with bowel preparation agents. The findings raise concerns about the presumed safety of PEG and reveal a strong disproportionality signal for bisacodyl. These results highlight the need for individualized bowel preparation strategies, especially in elderly patients with comorbidities."

Journal • Real-world evidence • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Immunology

Bisacodyl micro-enema before MRI of rectal tumors: effects on rectum, image quality and patient acceptance. (PubMed, Eur Radiol) - "Question Bisacodyl micro-enema can improve MRI of early stage-rectal tumors, but the impact on rectal physio-morphology, image quality, and patient acceptance is unknown. Result Bisacodyl micro-enema increased the submucosal width and intraluminal fluid, did not distend the rectum, improved image quality, and was well tolerated by the patients. Clinical relevance Bisacodyl micro-enema represents a reliable preparation before MRI of rectal tumors and can improve imaging of early-stage cancer. This is increasingly important because of the shift toward earlier stages due to screening programs and the growing use of organ-saving treatment."

Journal • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

Identification and validation of prognostic genes associated with mitochondrial nuclear genes in gastric cancer. (PubMed, Clin Exp Med) - "BMS-754807, Gefitinib, JQ1, Lapatinib, and Sapitinib exhibited significant differences in sensitivity between the high-risk group and the low-risk group. The results of molecular docking showed TP8A2 has stable binding ability with cytosine, COX15 with indomethacin, and TARS2 with bisacodyl. RT-qPCR revealed downregulation of ATP8A2 and upregulation of COX15 and TARS2 in GC samples. MNGs, including ATP8A2, COX15, and TARS2, demonstrated significant associations with immune infiltration, CNV, and prognostic outcomes of GC."

Biomarker • Journal • Gastric Cancer • Oncology • Solid Tumor